Interestingly, the combination of bortezomib/HDAC inhibitors resulted in a pronounced CD138+ bone marrow cell death from MM patients, but this effect was not observed in the CD138− cell population, suggesting a differential effect between tumoral PCs and MM-CSCs [140]. The gene discussed is SDC1; the disease is Miyoshi myopathy.